SCHEMBL13611501

SCHEMBL13611501

COC(=O)CC[C@H]1CCN(Cc2cc(C(F)(F)F)ccc2C(F)(F)F)[C@@H](C2C=CC(C(F)(F)F)=CC2)C1

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 17/20 0.37
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13611438 0.91 FFAR1 (0.39) FFAR1KMT2A
SCHEMBL13611611 0.85 FFAR4 (0.42) FFAR1
SCHEMBL8269169 0.83 GPBAR1 (0.36) —
SCHEMBL8267595 0.83 SCN1A (0.37) FFAR1KMT2A
SCHEMBL13611604 0.82 FFAR1 (0.33) FFAR1
SCHEMBL8269926 0.82 FFAR1 (0.33) FFAR1
SCHEMBL8268220 0.82 PPARD (0.36) —
SCHEMBL13513705 0.81 FFAR1 (0.40) FFAR1KMT2A
SCHEMBL8268235 0.81 FFAR4 (0.42) FFAR1
SCHEMBL8269182 0.81 DRD2 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638629-B2 Piperidines and related compounds for treatment of alzheimer's disease Merck Sharp & Dohme Ltd, (GB) 2009-12-29 — — US disclosed
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease PSEN1, PSEN2, APP FFAR1 1996/4885KMT2A 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback